ASX BRIEFS
Welcome to 'ASX BRIEFS,' the definitive podcast for enthusiasts, investors, and professionals keen on staying ahead of the curve in the Australian Stock Exchange (ASX). Hosted by Andrew Musgrave, 'ASX BRIEFS' delves deep into the heart of Australia's financial markets, bringing you insightful conversations with the minds shaping the future of investing down under. Each episode, join Andrew as he interviews a diverse lineup of fund managers, executives, and industry insiders, offering you a unique blend of expert analysis, strategic insights, and the latest trends affecting the ASX. Whether you're a seasoned investor or just starting out, 'ASX BRIEFS' is your go-to source for comprehensive updates and thought-provoking discussions designed to inform, inspire, and empower your investment journey. Tune in to 'ASX BRIEFS' and take the pulse of Australia's financial markets right at your fingertips.
ASX BRIEFS
ISLAND PHARMACEUTICALS (ILA) - Combating Mosquito-Borne Diseases: Island Pharmaceuticals' CEO Dr. David Foster on ISLA101's Potential and Strategic Roadmap
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Ever wondered how we can combat the surge of mosquito-borne diseases like dengue fever and Zika? Our latest podcast episode features an enlightening conversation with Dr. David Foster, CEO of Island Pharmaceuticals, who shares groundbreaking insights about their leading antiviral candidate, ISLA-101. Dr. Foster discusses the alarming rise in dengue cases, even in unexpected regions such as Queensland and parts of the United States, and how ISLA-101 could be a game-changer in both prevention and treatment of these diseases. Tune in to learn about the science behind repurposing existing molecules to fight all four strains of the dengue virus and other mosquito-borne illnesses.
In the second part of our episode, we delve into the strategic roadmap for Island Pharmaceuticals, exploring the commercial potential of ISLA-101 and future pipeline expansions. Dr. Foster details the significant market opportunities, from travel markets to government stockpile programs in Southeast Asia and Latin America. He also shares the company's innovative approach to acquiring new drug candidates and the importance of strategic collaborations, such as those with Monash University and the US Army. Don't miss out on hearing about the exciting milestones expected over the next 12 to 24 months and how Island Pharmaceuticals aims to make a lasting impact on global health.
Developing Antiviral Drug for Infectious Diseases
Andrew MusgraveWelcome to ASX Briefs . Today we're joined by Dr David Foster , the CEO of Island Pharmaceuticals , who are at the forefront of drug research and repurposing , focusing on antiviral therapeutics that addresses infectious diseases . Their lead product candidate , ISLA-101 , is aimed at combating dengue fever and other mosquito-borne diseases . David , thanks for joining us today and welcome to the podcast .
David FosterAndrew , thank you very much . I'm happy to be here .
Andrew MusgraveNow , David , could you provide us with a strategic overview of Island Pharmaceuticals and discuss the recent advancements with ISLA-101 , particularly in the context of its potential impact in the face of rising global dengue fever outbreaks ?
David FosterAbsolutely my pleasure , Andrew . So Island Pharmaceuticals is an antiviral drug development company at the highest level . That's what we're focused on . We like the approach of looking for molecules that have a clinical history sometimes a clinical history in a different indication and moving those molecules through the clinic in indications of interest for us . So antiviral therapeutics , for instance , we do have a lead program , as you mentioned , called ISLA- 101 . This is a program that is focused on dengue initially , and we're also , with ISLA-101 , have the ability to pursue other mosquito-borne viruses . So , interestingly , ISLA-101 has activity against all four strains of the dengue virus , which is very important . It also has activity , however , against Zika , West Nile , Yellow Fever , some of these other mosquito-borne viruses . It's a fascinating molecule . ISLA-101 was actually initially developed about 30 years ago by J&J and it was developed as a cancer drug . Yet it's never been approved for anything anywhere in the world . We came to it because we were looking for molecules that had activity against these viruses . So we found the molecule . We're moving through the clinic to develop this drug that could potentially be a preventative or potentially a treatment , and we're going to do clinical trials to study both .
David FosterAgain , looking at dengue first and then moving to other mosquito-borne viruses . I want to comment on something you said about the rise in dengue cases , and you're exactly right . What we're seeing , and we've seen even since we started this company , is that typically people think of dengue and other mosquito-borne viruses as tropical diseases , equatorial problems . And we've been saying for years and now we're starting to see it come true that the mosquitoes and the viruses they harbor are actually moving the regions of the world where they've not been seen before . So , for instance , even recently there was an outbreak of dengue in Queensland which , I would tell them very surprising .
David FosterThere's actually been several reports recently in Australia of alerts about dengue infections , and I see the same thing in the United States , where all of the Southern states in the United States Florida , Alabama , Texas and even California are now experiencing dengue infection . So it's a problem in places where we've not seen it before and then for those places where it's been traditionally endemic , they're having the worst outbreaks ever . Peru this year is having the worst dengue outbreak in the history of the country . So it's a huge problem and , frankly , there's really nothing that you can do about dengue and most of these mosquito-borne viruses . There's no effective treatment . There are limited available vaccines . The vaccines all come with challenges of their own . So you know it's a huge problem . There's 400 million dengue infections a year , there's probably around 50,000 deaths , and there's really nothing you can do about it right now . So we're excited by the challenge faced in front of us to develop a drug . That one , I think , could do a lot of good and potentially have big commercial opportunities .
Andrew MusgraveOkay , and the company has also established several key collaborations for drug research and development . Can you elaborate on these partnerships , especially your work with
David FosterAbsolutely , we have been blessed all along with relationships with great partners , and you're correct , Monash University is one of the first relationships that we established when we were beginning to look for molecules that had activity against these mosquito-borne viruses . We were looking for published literature , and work from Monash University really caught our eye because they had done some very elegant work describing the screening and the identification of a molecule that had anti-Dengue activity , and the more we looked at it we thought this is actually a molecule that makes a lot of sense and so we began conversations with Monash University . The molecule they identified turned out to be ISLA-101 . It was a molecule , again , that J&J had made many years before but never been approved . Monash discovered it while looking for an anti-dengue molecule . So we actually have licensed that IP portfolio for Monash University and are happy to be continuing to work with them . A second partner that we have a phenomenal relationship with is the US Army and the State University of New York in Syracuse , new York . It's SUNY Upstate . The relationship we have with these universities and with the Army is really important , especially as we're moving into an upcoming phase two clinical trial .
David FosterOur phase two clinical trial is a very interesting design called the challenge study , and by challenge study what I mean is we enroll healthy individuals and those individuals are infected with an attenuated or a weakened strain of the dengue virus . It's actually a virus that was an attempt to become a dengue vaccine , but it made people just a little bit sick and the US Army developed that , rather than discard that virus , they very cleverly said you know , we could actually study this virus , this mild , mild form of dengue in humans , and learn about the infection , which is what they've done . They've now run several subjects through clinical trials , just looking at the viral infection , with no drug on board . We actually have a CRADA , a Cooperative Research and Development Agreement in place with the US Army , and then the basis of that is they're going to give us the virus that they have developed running these challenge studies . They're also giving us the data out of the phase one studies that they run looking at the virus in untreated individuals , and that's very important for us because this really is the beginning of our controlled database . People who are infected with a virus that don't have drug on board , where we can measure viremia and we can measure symptoms associated with the dengue infection and , of course , the benefit is we don't have to pay for those individuals .
David FosterSo it's building our control database and we don't have to pay for it , and working with the Army is never a bad thing . I also mentioned SUNY Upstate . This is the site where we're going to be conducting the Phase II clinical trials . Suny works very closely with Walter Reed , the Army Medical Hospital , in handling these challenge studies . So again , very blessed with phenomenal partners .
Andrew MusgraveNow you've recently concluded the single ascending dose study with positive outcomes . What can you tell us about the results and their implications for the next phases of the drugs development ?
David FosterYeah , I'm very excited to tell you about this . So we have recently announced a couple of announcements describing the results obtained from our dose escalation study . This is a dose escalation study that we conducted in Australia and it's a single ascending dose , meaning we enroll healthy individuals and they get one dose of a drug . We take blood samples and measure the blood concentration of the drug for a period of time . The next group of individuals take a higher dose . The next group takes a higher dose .
David FosterThe goal of this is to see , first and foremost , as always , is it safe and well-tolerated ?
David FosterAnd we're happy to say that it was safe and well-tolerated at all doses that we tested .
David FosterThe second goal of the study is to say , if I give an individual a particular dose , what's the blood concentration that's going to be achieved following that over the course of the next several hours or even potentially days .
David FosterAnd we were very happy to see that the dose that we anticipate using in our upcoming phase two clinical trial achieves a blood concentration that's already been demonstrated to be effective at controlling the dengue virus . So that was the first thing we said it was safe and well tolerated and after a single dose we could achieve appropriate blood concentrations . We took the results from that a step further and did some in silico modeling and asked the question what is the blood concentration that is predicted to occur if we do multiple days of dosing ? And what the model predicts which is consistent with what's been observed previously with this drug is that for about three days blood levels rise and then they plateau after about three days and at all stages after the plateau the blood concentration is always above the concentration demonstrated to be effective against the virus . So with a lead that we've designed a phase two clinical trial based on the results that should be effective if we're going to see an effect .
Andrew MusgraveOkay , and from a regulation perspective , moving forward with the FDA's feedback , what are some of the strategic considerations and expected timelines for the Phase 2 study and how does this align with your regulatory goals ?
David FosterRight . So what we're doing right now is we're in the process of finalizing documents to file with the FDA to close out the dose escalation study I was just telling you about . We're also in the process of updating our phase two protocol that we're going to submit to the FDA . We expect these submissions to be submitted within the next few weeks . Following this , we will wait to hear from the FDA , giving the FDA time to review and comment on the submissions .
David FosterBut we aim to start screening for the phase two study , potentially as early early as July to screen and enroll for that clinical trial . This would enable us to start dosing in August . And I will tell you this is a very fast clinical trial when we're looking at infectious diseases . The life cycle of the dengue virus is about two weeks , so we'll know very quickly whether or not our drug is having an effect . And what that means for us as we move through multiple cohorts of the phase two study is we should begin dosing in August . We should be through dosing potentially as early as October . We should be seeing data beginning to come in by the end of this calendar year , with the full data package coming in probably in Q1 of 2025 . Again , it's very fast and we're excited about where we're headed with it .
Commercial Strategy and Pipeline Expansion
Andrew MusgraveAnd with ISLA- 101 showing potential for a priority review voucher and the expanding market for antiviral drugs . How is the company positioning itself commercially and what are the key markets you're looking to target ?
David FosterRight . So you raised a very interesting question talking about priority review voucher . Talking about priority review voucher , and at a very high level . The priority review voucher is an incentive program created by the FDA to encourage companies to develop drugs for underserved diseases . And if you check certain boxes and we have checked those boxes thus far and our program is eligible for a PRV you get a voucher that enables you to get expedited review of a second drug at the FDA , shaving several months of review time . And these can be very valuable . And the beautiful thing about the PRVs is that you can sell them . They typically sell for about $100 to $110 million US . Again , we wouldn't get it until the drug gets approved , but again , our program currently is eligible . So if that stays the same , then upon approval we would get this and we would expect to sell it , hoping that the price remains at around $100 to $110 million .
David FosterWe also think that there will be markets , considerable markets for a drug like ISLA-101 . On the one hand , we think travel markets would be very attractive . The closest proxy we have for a travel market prophylactic or therapeutic molecule is really the anti-malarial market and that's expected to approach about a billion dollar market opportunity by the year 2026 . And we think that's a pretty good proxy for what we're looking at . We also think that because Dengue is so prevalent in certain regions of the world , such as Southeast Asia or Latin America , that there's going to be opportunities there for governments to become our customers , to acquire the drug in stockpile programs that they can disseminate whenever they have outbreaks . So we think that there's many prongs for the commercial opportunity going forward .
Andrew MusgraveOkay , and besides ISLA- 101 , the company is actively exploring the acquisition or in licensing of new drug candidates . What's the criteria you're using to select these candidates and how do they fit into the broader company strategy ?
David FosterYes , we've been saying all along that we're focused on ISLA- 101 . We also would like to expand our pipeline and we want to expand our pipeline in a very considered approach and consistent with what we're doing with ISLA-101 . So the filters through which we analyze opportunities is we're looking for small molecules , molecules that have a clinical history , either in the antiviral space or even in other indications where we have evidence that they could have antiviral activity . We'd like to see opportunities for these molecules to be eligible for priority review vouchers if possible . That is certainly something we consider . We also look to say might these be supported by sources of non-dilutive funding ? We think that would be important if the governments we could obtain information , if governments were interested in supporting development of a program , that would be important for us . So when we look at these opportunities , we look at emerging infectious diseases or preparedness threats . These are some of the high-level things that we look at that I think . Check some of those boxes .
Andrew MusgraveAnd just in closing , can you give the audience a bit of an update on what are some of the key milestones you're looking to achieve in the next 12 to 24 months ?
David FosterAbsolutely so . With ISLA-101 , in the very short term , again beginning probably in July , you're going to start hearing a lot about our Phase 2 program . The Phase 2 program you're going to see us open that study . We'll begin enrolling , screening and enrolling individuals for that clinical trial . You'll see us dose the first subject . You'll see us move through the different cohorts of that phase 2 clinical trial and complete the dosing again probably in the October time frame . You'll also see us talking about the data coming out of that study towards the end of this calendar year and moving into the first quarter of next year .
David FosterUpon completion of that phase two study , we'll have an end of phase two meeting with the FDA and begin conversations about the subsequent study and what that's going to look like . We think that may look like a clinical trial , probably a therapeutic clinical trial in endemic countries , but that really remains to be finalized after conversations with the FDA . I think you're also going to see continued efforts in our pipeline expansion efforts and if things work out , we would love to have something to discuss . We don't have that right now but we're looking actively . So that's kind of where we're looking into the future .
Andrew MusgraveWell , there's obviously plenty of news on the horizon . So , David , thanks for your time today . It's been great to chat and we look forward to the next update from Ireland Pharmaceuticals in the coming months .
David FosterThank you so much for the time . It's been a pleasure . I appreciate it .
Andrew MusgraveThat concludes this episode of ASX Briefs . Don't forget to subscribe and we look forward to catching you on our next episode .